Patent intelligence · US
US 20260027049
AVACOPAN FORMULATIONS
AVACOPAN FORMULATIONS
Patent details — US 20260027049
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 29, 2026
- Expiration
- Jan 24, 2046
- Applicant
- AMGEN INC [US]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 31/ 451 A I, A61K 31/ 675 A I
Quick answer
US 20260027049 (AVACOPAN FORMULATIONS) is held by AMGEN INC [US]. Status: granted. Granted Jan 29, 2026. Expires Jan 24, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMGEN INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 08 A I, A61K 31/ 451 A I, A61K 31/ 675 A I, A61K 39/ 00 A I, A61K 47/ 14 A I
Related coverage
Frequently asked questions
What is US patent 20260027049?
US 20260027049 (AVACOPAN FORMULATIONS) is held by AMGEN INC [US]. Status: granted. Granted Jan 29, 2026. Expires Jan 24, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 20260027049?
AMGEN INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 20260027049 expire?
Our index shows an expiration date of Jan 24, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.